Scotiabank Maintains Outperform on Eli Lilly (LLY) Feb 2026, PT $1,300

Scotiabank maintained an Outperform rating on Eli Lilly and Company (LLY) on February 5, 2026, while raising its price target to $1,300. The firm issued the note at 10:43 AM and left the formal rating unchanged as Outperform, citing strong drug pipeline momentum. This LLY analyst rating update signals confidence from a major bank despite a recent share pullback of -1.93% or $-19.79 since the noted price point. Meyka AI, our AI-powered market analysis platform, tracks this action as part of real-time analyst coverage